Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Puthenveetil, Sujiet ^a,c   He, Haiyin ^a,d   Loganzo, Frank ^b   Musto, Sylvia ^b   Teske, Jesse ^a,c   Green, Michael ^a   Tan, Xingzhi ^b   Hosselet, Christine ^b   Lucas, Judy ^b   Tumey, L Nathan ^a   Sapra, Puja ^b   Subramanyam, Chakrapani ^a   O'Donnell, Christopher J ^a   Graziani, Edmund I ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Pfizer Oncology   (United States)

^c ABBVIE INC   (United States)

^d Biosortia Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; AZIDOACETYLSERYLLYCYLGLYCYLSERYLLYSINE THAILANSTATIN A; CYSTEINE THAILANSTATIN TRASTUZUMAB; MULTIDRUG RESISTANCE PROTEIN 1; THAILANSTATIN; THAILANSTATIN MULTI PAYLOAD CARRYING PEPTIDIC LINKER TRASTUZUMAB; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; DRUG CARRIER; PEPTIDE; PYRAN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STOMACH CANCER; CHEMISTRY; DRUG SCREENING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; PEPTIDES; PYRANS;

EID: 85020013576     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0178452     Document Type: Article

References (36)

1. Chari RVJ. Expanding the Reach of Antibody-Drug Conjugates. ACS Med Chem Lett. 2016;ASAP.
2. Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev. 2016.
3. Pietersz GA, Krauer K. Antibody-targeted drugs for the therapy of cancer. J Drug Target. 1994; 2 (3):183-215. https://doi.org/10.3109/10611869408996804 PMID: 7812691
4. Sochaj AM, Swiderska KW, Otlewski J. Current methods for the synthesis of homogeneous antibodydrug conjugates. Biotechnol Adv. 2015; 33(6 Pt 1):775-84.
5. Lhospice F, Bregeon D, Belmant C, Dennler P, Chiotellis A, Fischer E, et al. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. Mol Pharm. 2015; 12(6):1863-71. https://doi.org/10.1021/mp500666j PMID: 25625323
6. Hamann PR, Berger MS. Mylotarg: The first antibody-targeted chemotherapy agent. Tumor Targeting Cancer Ther. 2002:239-54.
7. Kim MT, Chen Y, Marhoul J, Jacobson F. Statistical Modeling of the Drug Load Distribution on Trastuzumab Emtansine (Kadcyla), a Lysine-Linked Antibody Drug Conjugate. Bioconjugate Chem. 2014; 25 (7):1223-32.
8. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30(7):631-7. https://doi.org/10.1038/nbt.2289 PMID: 22781692
9. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula Jagath R. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014; 6(1):34-45. https://doi.org/10.4161/mabs.27022 PMID: 24423619
10. Gao W, Zhang J, Xiang J, Zhang L, Wu C, Dhal PK, et al. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs). Curr Cancer Drug Targets. 2016; 16(6):469-79. PMID: 27174056
11. Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, et al. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics. J Control Release. 2016; 236:100-16. https://doi.org/10.1016/j.jconrel.2016.06. 025 PMID: 27327768
12. Tumey L. Nathan CAL, Vetelino Beth, Li Fengping, Rago Brian, Han Xiaogang, Loganzo Frank, Musto Sylvia, Bai Guoyun, Sukuru Sai Chetan K., Graziani Edmund I., Puthenveetil Sujiet, Casavant Jeffrey, Ratnayake Anokha, Marquette Kimberly, Hudson Sarah, Doppalapudi Venkata Ramana, Stock Joseph, Tchistiakova Lioudmila, Bessire Andrew J., Clark Tracey, Lucas Judy, Hosselet Christine, O'Donnell Christopher J., and Subramanyam Chakrapani. Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism. ACS Med Chem Lett. 2016; 7(11):977-82. https://doi.org/10.1021/acsmedchemlett.6b00195 PMID: 27882194
13. Schumacher D, Hackenberger CP, Leonhardt H, Helma J. Current Status: Site-Specific Antibody Drug Conjugates. J Clin Immunol. 2016; 36 Suppl 1:100-7. PubMed Central PMCID: PMC4891387.
14. Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, et al. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. J Med Chem. 2014; 57(19):7890-9. https://doi.org/10.1021/jm500552c PMID: 25191794
15. Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood. 2016; 127(1):71-8. PubMed Central PMCID: PMC4915807. https://doi.org/10.1182/blood-2015-07-604538 PMID: 26660428
16. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007; 3(9):576-83. https://doi.org/10.1038/nchembio.2007.18 PMID: 17643111
17. Roybal GA, Jurica MS. Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. Nucleic Acids Res. 2010; 38(19):6664-72. PubMed Central PMCID: PMC2965229. https://doi.org/10.1093/nar/gkq494 PMID: 20529876
18. Moldenhauer G, Salnikov AV, Luettgau S, Herr I, Anderl J, Faulstich H. Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma. J Natl Cancer Inst. 2012; 104(8):622-34. https://doi.org/10.1093/jnci/djs140 PMID: 22457476
19. Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, et al. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads. Bioconjug Chem. 2016; 27(8):1880-8. https://doi.org/10.1021/acs.bioconjchem.6b00291 PMID: 27412791
20. Dirico KJ, Eustaquio AS, Green ME, He H, He M, Koehn FE, et al., inventors; (Pfizer Inc., USA). assignee. Preparation of spliceostatin analog antibody conjugates for cancer treatment. Application: WOWOpatent 2013-IB59553 2014068443. 2014 20131022.
21. Puthenveetil S, Musto S, Loganzo F, Tumey LN, O'Donnell CJ, Graziani E. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. Bioconjug Chem. 2016; 27(4):1030-9. https://doi.org/10.1021/acs.bioconjchem. 6b00054 PMID: 26942771
22. Marquette K, Bennett E, Tchistiakova L, Tumey N, inventors; (Pfizer, Inc., USA). assignee. Engineered antibody constant regions for site-specific conjugation with therapeutic and for treatment of cancer, autoimmune, inflammatory, infectious or other disease. Application:WOWOpatent 2012-IB57491 2013093809. 2013 20121219.
23. Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015; 14(4):952-63. https://doi.org/10.1158/1535-7163.MCT-14-0862 PMID: 25646013
24. Matthew S. Sung XT, Christine Hosselet, Michael Cinque, Erik Upeslacis, Jonathon Golas, Fang Wang, Bingwen Lu, Laurie Tylaska, Lindsay King, Jeremy Myers, Edward Rosfjord, Judy Lucas, Hans-Peter Gerber, Frank Loganzo. Caveolae-mediated endocytosis as a novel mechanism of resistance to TDM1 ADC. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. Apr 16-20 ed. New Orleans, LA. Philadelphia (PA): AACR; 2016.
25. de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016; 40:14-23. https://doi.org/10.1016/j.coi.2016.02.008 PMID: 26963132
26. Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev. 2009; 109(7):2989-3011. https://doi.org/10.1021/cr9000226 PMID: 19583429
27. Kim EG, Kim KM. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul). 2015; 23(6):493-509. PubMed Central PMCID: PMC4624065.
28. Liu X, Biswas S, Berg MG, Antapli CM, Xie F, Wang Q, et al. Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43. J Nat Prod. 2013; 76(4):685-93. PubMed Central PMCID: PMC3696399. https://doi.org/10.1021/np300913h PMID: 23517093
29. He H, Ratnayake AS, Janso JE, He M, Yang HY, Loganzo F, et al. Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues. J Nat Prod. 2014; 77(8):1864-70. https://doi.org/10.1021/np500342m PMID: 25098528
30. Eustaquio AS, Janso JE, Ratnayake AS, O'Donnell CJ, Koehn FE. Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/alpha-ketoglutarate-dependent dioxygenase. Proc Natl Acad Sci U S A. 2014; 111(33):E3376-85. PubMed Central PMCID: PMC4143056. https://doi.org/10.1073/pnas.1408300111 PMID: 25097259
31. Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015; 525(7569):384-8. PubMed Central PMCID: PMC4831063. https://doi.org/10.1038/nature14985 PMID: 26331541
32. Albert BJ, McPherson PA, O'Brien K, Czaicki NL, Destefino V, Osman S, et al. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther. 2009; 8(8):2308-18. PubMed Central PMCID: PMC2762647. https://doi.org/10.1158/1535-7163.MCT-09-0051 PMID: 19671752
33. Nakajima H, Hori Y, Terano H, Okuhara M, Manda T, Matsumoto S, et al. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J Antibiot (Tokyo). 1996; 49(12):1204-11.
34. Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015; 33(7):733-5. https://doi.org/10.1038/nbt.3212 PMID: 26076429
35. Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug Chem. 2015; 26(4):650-9. https://doi.org/10.1021/bc5005747 PMID: 25643134
36. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance. Cancer Res. 2010; 70(6):2528-37. https://doi.org/10.1158/0008-5472.CAN-09-3546 PMID: 20197459